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Abstract: Bat rabies cases in Europe are mainly attributed to two lyssaviruses, namely European
Bat Lyssavirus 1 (EBLV-1) and European Bat Lyssavirus 2 (EBLV-2). Prior to the death of a bat
worker in Finland in 1985, very few bat rabies cases were reported. Enhanced surveillance in the two
subsequent years (1986–1987) identified 263 cases (more than a fifth of all reported cases to date).
Between 1977 and 2016, 1183 cases of bat rabies were reported, with the vast majority (>97%) being
attributed to EBLV-1. In contrast, there have been only 39 suspected cases of EBLV-2, of which 34 have
been confirmed by virus typing and presently restricted to just two bat species; Myotis daubentonii
and Myotis dasycneme. The limited number of EBLV-2 cases in Europe prompted the establishment of
a network of European reference laboratories to collate all available viruses and data. Despite the
relatively low number of EBLV-2 cases, a large amount of anomalous data has been published in the
scientific literature, which we have here reviewed and clarified. In this review, 29 EBLV-2 full genome
sequences have been analysed to further our understanding of the diversity and molecular evolution
of EBLV-2 in Europe. Analysis of the 29 complete EBLV-2 genome sequences clearly corroborated
geographical relationships with all EBLV-2 sequences clustering at the country level irrespective of the
gene studied. Further geographical clustering was also observed at a local level. There are high levels
of homogeneity within the EBLV-2 species with nucleotide identities ranging from 95.5–100% and
amino acid identities between 98.7% and 100%, despite the widespread distribution of the isolates
both geographically and chronologically. The mean substitution rate for EBLV-2 across the five
concatenated genes was 1.65 × 10−5, and evolutionary clock analysis confirms the slow evolution of
EBLV-2 both between and within countries in Europe. This is further supported by the first detailed
EBLV-2 intra-roost genomic analysis whereby a relatively high sequence homogeneity was found
across the genomes of three EBLV-2 isolates obtained several years apart (2007, 2008, and 2014) from
M. daubentonii at the same site (Stokesay Castle, Shropshire, UK).
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1. Introduction
There are currently 14 recognised species in the lyssavirus genus of the family Rhabdoviridae [1].
These species are comprised of the following viruses: rabies virus (RABV), Lagos bat virus (LBV),
Mokola virus (MOKV), Duvenhage virus (DUVV), European bat lyssavirus 1 (EBLV-1), European bat
lyssavirus 2 (EBLV-2), Australian bat lyssavirus (ABLV), Aravan virus (ARAV), Khujand virus (KHUV),
Irkut virus (IRKV), West Caucasian bat virus (WCBV) Shimoni bat virus (SHIBV), Ikoma virus (IKOV),
and Bokeloh bat lyssavirus (BBLV). A further two putative bat lyssaviruses await classification: Lleida
lyssavirus (LLEBV) [2] and Gannoruwa bat lyssavirus (GBLV) [3]. With the exception of MOKV and
IKOV, all lyssaviruses have been isolated from bats.
Cases of bat rabies occur globally, although different bat lyssavirus species are present in different
regions [4,5]. Bat rabies cases in Europe are principally attributed to EBLV-1 and EBLV-2. However,
three other lyssaviruses have been detected in European insectivorous bats, albeit in very few cases.
WCBV was isolated in 2002 from a bent-winged bat (Miniopterus schreibersii) in the Caucasus Mountains
and LLEBV from the same bat species in Spain in 2011 [2,6]. Antigenic and phylogenetic profiling of
BBLV, isolated from Myotis nattererii in Germany and France, confirms the presence of a fifth lyssavirus
in European bats [7–9].
The first record of a lyssavirus infected insectivorous bat in Europe was in Hamburg, Germany,
in 1954 [10]. The reports described a biting incident from a bat that was caught and tested but not
formally identified. Negri bodies were detected following mouse inoculation tests, but no tissue was
retained for virus typing, so the bat and virus species involved are unknown. Prior to the death of a bat
worker in Finland in 1985 [11], very few bat rabies cases were reported. Interestingly, 23% (263 cases)
of all subsequent reported cases were identified through enhanced surveillance in the subsequent
two years (1986 and 1987). With the advent of molecular PCR assays (polymerase chain reaction) and
subsequent sequencing, the viruses were genetically characterised as two separate lyssavirus species,
EBLV-1 and -2 [12].
Between 1977 and 2016, 1183 infected bats were reported in Europe with an average of 34
infected bats reported per year to Rabies Bulletin Europe in the last decade. More than 80% of the
reported cases were identified in three countries the Netherlands (33%), Germany (27%), and Denmark
(21%). Differences in surveillance systems, bat ecology, public awareness, and available resources
may account for the heterogeneous spatial pattern of confirmed bat rabies cases [13]. However, the
apparent host specificity may also limit the prevalence of bat lyssaviruses when considering the wide
distribution, high frequency, and sympatric habitation of some European insectivorous bat species.
Whilst lyssaviruses have the ability to cause clinical disease in bats, they can also circulate within
healthy bat populations detectable only via active surveillance screening [14,15].
Cross species transmission (CST) of bat lyssaviruses to other mammals has been documented but
is extremely rare [16]. Two CST events involving EBLV-2 from bats to humans have been reported,
in Finland in 1985 and in the UK in 2002. Unlike for EBLV-1, EBLV-2 spillover into other wildlife or
domestic species has not been documented and no other lyssavirus has yet been isolated from M.
Daubentonii or M. dasycneme.
Evolutionary analyses, sub-clinical infections and restricted virus–host relationships suggest
that all lyssaviruses, including RABV, most likely originated in bats [16–18]. Previous attempts
to study the phylogeography, molecular epidemiology, and evolutionary rates for EBLV-2 have
been restricted to only a small number of virus isolates or partial genomic sequences [19–21].
The historic sharing of viruses between European rabies laboratories for confirmation and research
was not standardised. This is particularly evident for the EBLV-2 viruses due to the small number
involved. However, differences in virus handling (multiple passages in vivo and in vitro), various
sequencing approaches (direct sequencing from amplicons, sequencing from cloned products, and deep
Int. J. Mol. Sci. 2018, 19, 156 3 of 16
sequencing), and improvements in the proof reading fidelity of molecular enzymes have resulted in
anomalous published sequences being submitted for the same isolate [20]. To address this, a network
of rabies reference laboratories involved in EBLV-2 surveillance and diagnosis was established to
review, collate, and analyse all available EBLV-2 submissions. The aim of this review was to collate and
analyse a comprehensive and accurate genomic sequence dataset for EBLV-2 providing researchers
with both epidemiological and genetic data for every confirmed case. Furthermore, whole genome
sequences from the same site were analysed to understand the diversity of viruses within the same
maternity roost.
2. Results and Discussion
2.1. Review of Reported Cases
Data from all potential cases of EBLV-2 were collated. The distribution and submission details are
summarised in Figure 1 and Table 1 and include confirmed cases of EBLV-2.
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EBLV-2 was first isolated in 1985 from a Swiss bat biologist who had been working with bats in 
Finland, Switzerland, and Malaysia. In 1986, EBLV-2 was isolated in Switzerland from M. daubentonii 
(Daubenton’s bats). Between 1985 and 2017, a total of 39 cases are suspected to have been associated 
with EBLV-2, of which 34 have been confirmed (Table 1). Full genome sequences have been 
previously published or obtained in this study for 29 EBLV-2. In addition, EBLV-2 RNA has been 
detected by RT-PCR in oro-pharyngeal swabs of two apparently healthy M. daubentonii bats during 
active surveillance (Scotland and Switzerland), yielding partial N gene sequences (Table 1). 
Unfortunately, sequence data obtained for three outstanding EBLV-2 cases (UK RV3385, Germany 
F860/LGL and 2Finland2016) were obtained too late to be included in this analysis. Assuming that 
rabies in M. daubentonii and M. dasycneme (Pond bats) is restricted to EBLV-2 infection, there were 
three further probable EBLV-2 cases in Denmark from single M. dasycneme (1986, 1987) and M. 
daubentonii (1986) bats [22]. In Germany, bat rabies was diagnosed in two M. daubentonii in 1986 [23]. 
However, no material is available for confirmation of an EBLV-2 infection from these probable cases 
so they remain unconfirmed. The total number of confirmed (typed) EBLV-2 cases is relatively small 
compared to EBLV-1 isolated from Eptesicus bat species. This discrepancy could be due to less 
effective surveillance in non-synanthropic bat species like Daubenton’s bats compared to Eptesicus 
bats or the low transmission rates of EBLV-2 among conspecifics as indicated by experimental studies 
in Daubenton’s bats [24]. 
Figure 1. Distribution of 34 confirmed cases of EBLV-2 (Table 1) in Europe between 1985 and 2017
(WHO Rabies Bulletin Europe).
EBLV-2 was first isolated in 1985 from a Swiss bat biologist who had been working with
bats in Finland, Switzerland, and Malaysia. In 1986, EBLV-2 was isolated in Switzerland from M.
daubentonii (Daubenton’s bats). Between 1985 and 2017, a total of 39 cases are suspected to have been
associated with EBLV-2, of which 34 have been confirmed (Table 1). Full genome sequences have
been previously published or obtained in this study for 29 EBLV-2. In addition, EBLV-2 RNA has
been detected by RT-PCR in oro-pharyngeal swabs of two apparently healthy M. daubentonii bats
during active surveillance (Scotland and Switzerland), yielding partial N gene sequences (Table 1).
Unfortunately, sequence data obtained for three outstanding EBLV-2 cases (UK RV3385, Germany
F860/LGL and 2Finland2016) were obtained too late to be included in this analysis. Assuming
that rabies in M. daubentonii and M. dasycneme (Pond bats) is restricted to EBLV-2 infection, there
were three further probable EBLV-2 cases in Denmark from single M. dasycneme (1986, 1987) and
M. daubentonii (1986) bats [22]. In Germany, bat rabies was diagnosed in two M. daubentonii in 1986 [23].
However, no material is available for confirmation of an EBLV-2 infection from these probable cases
so they remain unconfirmed. The total number of confirmed (typed) EBLV-2 cases is relatively small
compared to EBLV-1 isolated from Eptesicus bat species. This discrepancy could be due to less effective
surveillance in non-synanthropic bat species like Daubenton’s bats compared to Eptesicus bats or
the low transmission rates of EBLV-2 among conspecifics as indicated by experimental studies in
Daubenton’s bats [24].
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Table 1. Confirmed cases of EBLV-2 in Europe 1985–2017 and sequences used to generate phylogenetic trees.
Year Original Reference APHA Virus Ref. PI Virus Ref. Location Country Species N400 Data Accession No. Genome Accession No. Case or Sequence Ref.
1985 FINMAN RV8 9007FIN Helsinki Finland Human AY062091 JX129233, KY688151 [11]
1987 41729 RV30 9018HOL Wommels Netherlands M.dasyc EU293114 EU293114 [19]
1987 47072 RV29 9482HOL Tjerkwerd Netherlands M.dasyc U89480 KY688145 [25]
1989 92666 RV228 94112HOL Andijk Netherlands M.dasyc AY062089 KY688146 [19]
1992 TW1814/92 RV594, RV2478 - Plaffeien Switzerland M.daub. AY212117 KY688133 [26]
1993 - - 9375HOL Roden Netherlands M.dasyc AY863404 KY688152 [19]
1993 TW1392/93 RV621, RV2479 9337SWI Versoix Switzerland M.daub AY212118 KY688140 [19]
1996 18/96 RV628 EBL2GB Sussex England M.daub U89478 KY688136 [27]
2002 105/02 RV1332 - Lancashire England M.daub AY212120 KY688150 [28]
2002 Human case RV1333 - Angus Scotland Human EF157977 EF157977 [29]
2002 TW0118/02 RV2480 02053SWI Geneva Switzerland M.daub AY863408 KY688132 [19]
2004 603/04 RV1787 - Surrey England M.daub JQ796807 KY688142 [30]
2003 696/04 RV1788 - Lancashire England M.daub JQ796808 KF155004 [31]
2006 672/06 RV2159 - Oxfordshire England M.daub JQ796809 KY688144 [32]
2006 18856 RV2506 - Magdeburg Germany M.daub JQ796805 KY688135 [33]
2006 25538 - - Thuringia Germany M.daub KF826115 KY688137 [34]
2007 16618 RV2505 - Bad Buchau Germany M.daub GU227648 KY688138 [35]
2007 762/07 RV2336 - Shropshire England M.daub JQ796810 KY688139 [36]
2008 166/08 RV2418 - Surrey England M.daub JQ796811 KY688141 [37]
2008 1218/08 RV2473 - Shropshire England M.daub JQ796812 KY688147 [38]
2009 882/09 RV2482 - West Lothian Scotland M.daub JQ796806 KY688143 [39]
2009 ra3278/09 - - Nr Turku Finland M.daub GU002399 JX129232 [40]
2012 F500/LGL - - Ingolstadt,Bavaria Germany M.daub - KY688149 [34,41]
2013 31452 - - Gießen, Hesse Germany M.daub KF826149 KY688134 [34]
2013 F860/LGL - - Ingolstadt,Bavaria Germany M.daub - Not available This study
2014 281/14 RV2974 - Shropshire England M.daub - KY688148 This study
2015 421/15 RV3158 - Newtown,Powys Wales M.daub - KY688153 This study
2015 2015-04-18832 - - Oppland Norway M.daub - KY688154 [42]
2016 307/16 RV3369 - North Yorkshire England M.daub - KY688156 This study
2016 432/16 RV3370 - Northumberland England M.daub - KY688155 [43]
2016 2Finland2016 - - Inkoo, Uusimaa Finland M.daub MF326269 Not available [44]
2017 591/17 RV3385 - Derbyshire England M.daub - Not available This study
Active Surveillance Detection of Viral RNA in Oro-Pharyngeal Swab Only:
2008 80063 M08/09 - Perthshire Scotland M.daub JQ796804 Not available [20]
2009 70 - - Genthod Switzerland M.daub HM067110 Not available [26]
Key—not known. M.daub—Myotis daubentonii; M.dasyc—Myotis dasycneme.
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Fourteen cases of EBLV-2 in M. daubentonii were reported through passive surveillance in the UK
between 1996 and 2017 and a single human case in a male in Scotland in 2002 [29]. Unfortunately,
sequence data from the latest UK case in September 2017 (Table 1, Derbyshire, England) was obtained
too late to be included in the phylogenetic analysis in this review. However, preliminary sequence
analysis (N1356) suggests a closer identity (99.6%) to the 1996 EBLV-2 RV628 and 2006 EBLV-2 RV2159
cases (Table 1, Sussex and Oxfordshire, respectively). In addition, EBLV-2 viral RNA was detected in a
single oro-pharyngeal swab specimen collected from a healthy Daubenton’s bat sampled as part of an
active surveillance programme in Scotland in 2008 [20].
The discovery of EBLV-2 in M. daubentonii in Finland (2009) provided evidence for the possible
origin of human infection in 1985 [40]. Prior to this latter case, surveillance had failed to detect
EBLV-2 in Finland despite intensive efforts in 1986 by active surveillance [45] and continued passive
surveillance since (albeit for low submissions averaging 10/year). Subsequent active surveillance has
failed to detect viral RNA in the oro-pharyngeal swabs of healthy Daubenton’s bats [46]. A second
case of EBLV-2 in M. daubentonii has more recently been reported in Inkoo, Southern Finland (October
2016) but genome sequence case was not available for this review [44]. However, partial N gene data
(N253, accession number MF326269) confirms a closer sequence identity (97.6–98%) to the previous 2
Finland EBLV-2 cases than to any other EBLV-2 (91.7–95.7%).
In Germany, six rabies cases in Daubenton’s bats have been typed as EBLV-2 [33–35,41], and five
genome sequences were available to be included in this study. Notably, only one case was detected
in the frame of routine rabies surveillance, whilst the other five isolates were only found during
enhanced surveillance programmes targeting all dead found bats [34]. Genomic sequence data for the
outstanding German case (Table 1, Bavaria 2013 860/LGL) were obtained too late to be included in
this study, but preliminary sequence analysis (N1336) confirms the closest sequence identity to the
2012 Bavarian German EBLV-2 F500/LGL (99.8%).
The Netherlands is the only country where EBLV-2 was detected in M. dasycneme bats [47],
of which sequences are available for four isolates (Table 1). Interestingly, passive surveillance has not
yielded any further EBLV-2 cases since 1993.
In Switzerland, passive surveillance between 1976 and 2009 revealed three cases of EBLV-2, all
in M. daubentonii and a single PCR positive oro-pharyngeal swab sample via active surveillance [26].
The three Swiss EBLV-2 isolates identified through passive surveillance have previously been
analysed [19,20,26,48], but discrepancies in the sequence obtained for the three isolates were noted
between different studies. In addition, it is unclear if the partial N gene sequence published as U89479,
which shows a number of mismatches compared to all other Swiss EBLV-2 sequences, represents an
additional Swiss virus or is a result of erroneous sequencing. In order to solve these issues, original
virus isolates for the Swiss EBLV-2 held at APHA and University of Berne were subject to NGS and the
correct genome sequences were obtained in this study (Table 1).
The first case of EBLV-2 in Norway was reported in a Daubenton’s bat in 2015. The bat was found
by a member of the public in Oppland, in the southern part of Norway [42].
2.2. Phylogenetic Analysis
The phylogenetic analysis confirmed the close relationship of EBLV-2 sequences to the Phylogroup
I lyssaviruses, in particular KHUV and BBLV, irrespective of the gene studied (Figure 2a,b, maximum
likelihood trees for other genes not shown). Where available, a number of representative lineages for
the lyssaviruses were included. The genetic diversity observed for the other lyssavirus species is in
contrast to the highly homogeneous sequence identities observed for EBLV-2. However, despite this
homogeneity, the EBLV-2 sequences are resolved geographically for all analyses, with clear clustering
at the country level. Even within country, resolution can be observed when sufficient numbers allow.
The Scotland and Northern England EBLV-2 isolates can be seen to cluster separately to the Southern
England and Wales EBLV-2 isolates, although bootstrap support is not consistent (Figures 2 and 3).
The human EBLV case (RV1333) in Scotland in 2002, resolved closest to the Northern England and
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Scotland cases. In the partial N400 analysis (not shown), human UK EBLV-2 was most similar to the
partial sequence obtained from a Daubenton’s saliva sample during active surveillance in Scotland [20].
Although originating from disparate regions in the south and north of Germany, the German EBLV-2
viruses cluster together and are most closely associated with the 2002 Swiss isolate (TW0118/02)
(Figure 2). All of the Dutch EBLV-2 sequences cluster separately from the other sequences possibly
reflecting either geographical and/or host species relationships. The latter may be likely as the EBLV-2
isolates from the Netherlands are the only ones sampled from M. dasycneme. The Norwegian EBLV-2 is
distinct but is most closely related to the Swiss EBLV-2.
The two available EBLV-2 genome sequences from Finland are clearly distinct from the other
EBLV-2 studied and have previously been proposed as a separate lineage, although depending upon
the gene studied, the bootstrap support is not always consistent. However, the relatively low number
of available EBLV-2 sequences makes it difficult to confidently further divide into monophyletic
sub lineages. Although, the subtypes 2a and 2b of EBLV-2 were proposed in earlier studies [48],
it has more recently been reported that the highest nucleotide sequence divergence was between two
isolates (AY863408—Switzerland isolate and AY863406—Finland human case), previously assigned
as EBLV-2b [49]. The two EBLV-2 sequences from Finland [21] and the erroneous sequence U89479
consistently formed a well-supported sub lineage (EBLV-2b?) irrespective of the model used (bootstrap
support 100% for Neighbour Joining (p-values) and 99% for Maximum Likelihood (GTR) models).
In contrast, the 1992 & 1993 Swiss EBLV-2 sequences were not consistently associated with either
sub-lineage when individual sequences were removed or additional lyssavirus sequences added.
Intra-genotypic comparisons were reported previously for the five viral proteins of EBLV-2 [49]
and demonstrated the limited genetic diversity of these lyssaviruses compared to RABV at both the
nucleotides and amino acid levels. In these analyses, using concatenated gene sequences, the similarity
of the EBLV-2 ranged from 95.5–100% for nucleotides and from 98.7–100% for amino acids.
With respect to the anomalous sequence U89479, no evidence has been found to support it as an
additional EBLV-2 sequence, hence we conclude it is erroneous and recommend it is not used in future
EBLV-2 analyses.
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Figure 3. Bayesian maximum clade credibility (MCC) tree of 29 EBLV-2 concatenated gene
sequences (10818 nucleotide sites comprising the nucleoprotein, matrix, phosphoprotein, glycoprotein,
and polymerase genes) with branch lengths scaled in time by enforcing a relaxed molecular clock.
The EBLV-2 strains are coloured to indicate the location of sampling. Mean substitution rate of the
dataset was 1.7 × 10−5.
2.3. Intra-Roost Variation
The three EBLV2 isolates from Daubenton’s bats found at Stokesay castle (Shropshire, UK) were
studied in greater detail as they represented the only cluster of EBLV-2 with three separate isolations at
the same site in 2007, 2008, and 2014. The percentage of viral reads assembled from the total reads
varied between isolates, ranging from 0.98% (RV2473) to 2.08% (RV2336). Depth of coverage (average
and maximum) was variable and correlated with the number of viral reads assembled (Table S1).
The three genomes were aligned and found to be 99.9% identical to one another. Positions at
which single nucleotide polymorphisms (SNPs) occurred were identified and investigated to determine
whether they denote a change in amino acid within a region of the genome coding for a viral protein
(Figure 4). Surprisingly, only one such SNP was identified within the P gene at Position 2015, despite
up to a 7-year interval between isolations. RV2336 and RV2974 code for lysine at this position, whereas
the change in base from A to G in RV2473 results in the translation of arginine instead (Table S2). This
SNP is located within the LC8 domain (cytoplasmic dynein light chain) at residue 164. The LC8 domain
has been previously identified as a region at which the P protein interacts with LC8, a cytoplasmic
protein associated with axonal transport of RABV within neurons [49,50], but the SNP is not within
the key residues of 145–149, the motif to which LC8 binds. In addition, the substitution is considered
conservative due to the similar biochemical properties of the amino acids.
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2.4. Evolutionary Analysis of EBLV-2
Evolutionary analysis was undertaken using an alignment of concatenated genes for the 29 EBLV-2
sequences. The analysis supports the previously observed relatively low evolutionary rates for EBLV-2
compared to other RNA viruses [19,21]. The ancestral root of the available EBLV-2 concatenated dataset
was likely to have diverged as far back as 436AD, but the 95% HPD intervals are wide (−9553 to 1655).
The recent ancestors of the geographical clusters of EBLV-2 are estimated as follows (Figure 3); Finland
in 1880 (range 1133 to1969), Norway in 706 (single isolate −7535 to 1664); Switzerland in 890 (−6280
to 1734), Germany in 1567 (−1326 to 1910); Netherlands in 1862 (1042 to 1961); UK in 1639 (−727 to
1923). The Stokesay EBLV-2 ancestors are estimated to have existed much more recently in 1970 (1725
to 2003). The long TMRCAs observed (Figure 3) is suggestive of minimal and discrete evolution at the
local level (Figure 3). Migration of infected bats, whilst possible, does not appear to be supported in
our dataset. Mean rate of evolution for the concatenated genes for the EBLV-2 dataset (n = 29) was
1.7 × 10−5 (4.65 × 10−8, 3.63 × 10−5).
3. Materials and Methods
Firstly, a literature review was undertaken of all reported cases of EBLV-2 between 1985 and 2017.
As well as peer-reviewed literature and published sequences on GenBank, other sources included
Rabies Bulletin Europe Reports, ProMed reports, and reference laboratory archives. When available
and where gaps existed, original brain material was sought to clarify anomalies in published data and
obtain complete genome sequences (Table 1).
3.1. Next Generation Sequencing (NGS)
Total RNA (from original brain material) was depleted of host genomic DNA (gDNA) and
ribosomal RNA (rRNA) following methods described previously [51,52]. Briefly, gDNA was depleted
using the on-column DNase digestion protocol in RNeasy plus mini kit (Qiagen, Manchester, UK)
following manufacturer’s instructions, eluting in 30 µL in molecular grade water. Subsequently, rRNA
was depleted, using Terminator 5′-phosphate-dependent exonuclease (CamBio, Cambridge, UK).
Briefly, 30 µL of gDNA depleted RNA was mixed with 3 µL of Buffer A, 0.5 µL of RNAsin Ribonuclease
inhibitor (20–40 U/µL) (Promega, Southampton, UK), and incubated at 30 ◦C for 60 min. The depleted
RNA was purified to remove the enzyme using the RNeasy plus mini kit as above, without the DNase
digestion, eluting in 30 µL of molecular grade water. ds cDNA (double-stranded copy DNA) was
synthesised using random hexamers and a cDNA synthesis kit (Roche, Burgess Hill, UK) following
manufacturer’s instructions. The resulting ds-cDNA was purified using AMPure XP magnetic beads
(Beckman Coulter, High Wycombe, UK), quantified using Quantifluor (Promega) and approximately
1 ng of each sample was used in a “tagmentation” reaction mix using a Nextera XT DNA sample
preparation kit (Illumina, San Diago, CA, USA) following the manufacturer’s instructions—without
the bead normalization step. DNA libraries were quantified using Quantifluor (Promega). Individual
libraries were pooled (approximately 8–12 samples per MiSeq run) and normalized to equimolar
concentrations. Libraries were sequenced as 2 × 150 bp paired-end reads on an Illumina MiSeq
platform (Illumina).
3.2. Mapping to Reference Sequence to Obtain Complete Genome Sequences
Reads were mapped using the Burrow–Wheeler Aligner (BWA version 0.7.5a–r405) and were
visualized in Tablet [53]. A modified SAMtools/vcfutils [54] script was used to generate an intermediate
consensus sequence in which any indels and SNPs relative to the original reference sequence were
appropriately called. The intermediate consensus sequence was used as the reference for four
subsequent iterations of mapping and consensus calling. Sequencing resulted in 100% coverage
of the five genes for all samples. Consensus sequences were submitted to Genbank (accession numbers
provided in Table 1).
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3.3. Evolutionary Analysis
Sequences generated in this study were combined with published EBLV-2 sequences and aligned
using ClustalX2 (version 1.2, www.clustal.org/clustal2). Nucleotide and amino acid identities were
obtained using MegAlign, v11.1.0 (Lasergene DNASTAR. Madison, WI, USA).
A phylogenetic analysis of all 29 EBLV-2 concatenated coding gene sequences (Accession numbers
provided in Table 1) was undertaken using Bayesian Markov Chain Monte Carlo simulation in the
BEAST package v1.8.0 [55]. A GTR nucleotide substitution model with rate variation and a proportion
of invariant sites (Gamma) were determined to best fit the data using Akaike Information Criterion
(AIC) in MEGA 6.0 [56]. A relaxed molecular clock model with constant population prior were used in
Markov Chain Monte Carlo (MCMC) simulation for 100,000,000 iterations, sampling every 10,000 states
to give effective sample sizes of over 200. Molecular clock and population coalescent models were
compared using a modified AIC (AICM) in Tracer v1.5, as described previously [57], and maximum
clade credibility trees were annotated using TreeAnnotator (v1.8.4) after 10% of trees (burn-in) were
discarded [55]. The maximum clade credibility (MCC) trees were then visualised using Fig Tree (v1.4.3,
http://tree.bio.ed.ac.uk/software/figtree/). Maximum likelihood phylogenetic reconstructions were
also undertaken on the EBLV-2 dataset (n = 29) in MEGA 6.0 [56] for each individual gene and for
partial N gene sequences (400 nucleotides).
4. Conclusions
This review represents the most comprehensive and accurate genomic analysis of EBLV-2 to
date and includes the first detailed intra-roost genetic analysis of EBLV-2 isolated from the same site
between 2007 and 2014.
The chiropteran host range of confirmed EBLV-2 appears to be restricted to two bat species
M. Daubentonii (n = 28) and M. dasycneme (n = 5) (Table 1). The distribution of M. dasycneme is confined
to Central and Eastern Europe, whereas M. daubentonii is widely distributed throughout Europe [58].
M. dasycneme is considered to be absent in the UK. However, given the relationship between bat species
and their lyssaviruses [4], it remains unclear as to whether M. dasycneme is a true reservoir for EBLV-2
or whether these cases represent spill over infections. The genetic structure of M. daubentonii in Western
Europe is relatively homogenous and data suggests migratory movements between the UK and the
mainland Europe by Daubenton’s bats [59]. Many factors affecting the behaviour of Daubenton’s bats,
may allow EBLV-2 to become established and rapidly spread throughout the population. This may
account for the greater detection of EBLV-2, albeit at low levels, throughout the UK [60]. However,
despite the long distance migratory behaviour of Daubenton’s bats [61] and the extended distribution
of EBLV-2 across Europe, there is a striking spatial clustering of EBLV-2 sequences, irrespective of the
genomic region analysed.
Within EBLV-2 there is a high level of sequence homogeneity and low evolutionary rate compared
to other lyssaviruses. The intra-roost analysis of the three Stokesay EBLV-2 genomes sampled within a
7-year period demonstrates extremely few SNPs and insignificant levels of heterogeneity in the viral
reads. However, partial sequence analysis would have been limited in differentiating the isolates, thus
confirming the importance of generating full genome/concatenated gene data to improve resolution.
The low mean substitution rate of 1.7 × 10−5 of the EBLV-2 concatenated gene dataset is similar to the
4.19 × 10−5 rate recently determined for EBLV-1 [62] but contrasts starkly with rates published for
similar concatenated gene or complete genome datasets for RABV, e.g., 3.10 × 10−4 for Turkey canine
RABV dataset [63], a comprehensive canine RABV dataset 2.44 × 10−4 [64] and a fox RABV dataset
from Greenland 2.5 × 10−4 [65]. The long TMRCAs and low substitution rate suggests limited and
localised evolution has occurred over very long periods of time. The distribution and evolutionary
analysis suggest an east–west axis possibly in an east (Finland) to west (UK) direction (Figures 1 and 3).
In recent years, multiple novel lyssaviruses have been isolated from bats. Passive bat surveillance,
complemented by active surveillance where appropriate, will facilitate the further isolation of known
and novel bat lyssaviruses. To fully assess the diversity and evolution of bat lyssaviruses in Europe,
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all isolates from bat rabies cases should be archived and further characterized. Molecular typing
of wildlife rabies cases will facilitate the early detection of CST events which could give rise to the
adaption and maintenance of bat lyssaviruses in non-flying mammals. As confirmed in this study,
NGS offers unique insights into viral evolution. For a virus with relatively few cases, it is prudent
to obtain full genome sequence and study the possible causes for such limited viral evolution and
restricted host range [16].
Supplementary Materials: Supplementary materials can be found at www.mdpi.com/1422-0067/19/1/156/s1.
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